Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

• Mark R Middleton,
• Winald R Gerritsen,
• Ian Walters,
• Licia Rivoltini,
• Niven Mehra,
• Jeroen H A Creemers,
• Carl G Figdor,
• I Jolanda M de Vries,
• Uzi Gileadi,
• Inka Pawlitzky,
• Konstantina Grosios,
• Petronella B Ottevanger

Affiliations

Mark R Middleton

2 Oncology, Churchill Hospital, Oxford, UK

Winald R Gerritsen

4 Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands

Ian Walters

4Intensity Therapeutics, Westport, CT, USA

Licia Rivoltini

Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Niven Mehra

4 Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands

Jeroen H A Creemers

1 Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands

Carl G Figdor

1 Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands

I Jolanda M de Vries

1 Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands

Uzi Gileadi

MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford, UK

Inka Pawlitzky

CATO SMS, Amsterdam, The Netherlands

Konstantina Grosios

oncoKnow, Amsterdam, The Netherlands

Petronella B Ottevanger

Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands